8-Hydroxyquinoline Derivatives for Metal Chelation in Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and other neurological disorders lack effective metal-chelating agents to modulate metal-Aβ interactions, leading to inadequate management of these conditions.
Innovation Solution
Development of 8-hydroxyquinoline derivatives that act as potent metal chelators, capable of selectively binding Cu and Zn ions, which can be used therapeutically and as radiopharmaceuticals for diagnostic imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Alzheimer's disease are used, then symptom alleviation is achieved, but effective metal-chelating activity to modulate metal-Aβ interactions is lacking
Solution Approach 1:
The patent extracts and removes the harmful metal ions (Cu and Zn) from the metal-Aβ interaction system by introducing 8-hydroxyquinoline derivative compounds that selectively chelate these metal ions. The compounds contain specific functional groups (hydroxyl, carbonyl, and heteroatom groups) that bind to metal ions, extracting them from the pathological Aβ deposits and preventing their harmful interaction with amyloid-beta peptides.
Solution Approach 2:
The 8-hydroxyquinoline derivatives act as intermediary agents between the metal ions and the Aβ deposits. These compounds serve as mediators that facilitate the removal of metal ions from the pathological complexes through their chelating capability, while the radioisotope-labeled versions also serve as intermediaries for diagnostic imaging of metal distribution in tissues.
2Reliability
If metal chelating agents are introduced to dissolve Aβ deposits, then metal-Aβ interaction is prevented, but diagnostic capability for monitoring disease progression is insufficient
Solution Approach 1:
The patent creates multi-functional compounds that simultaneously provide therapeutic metal-chelating activity and diagnostic imaging capability. The 8-hydroxyquinoline derivatives are designed with radioisotope labels (such as 64Cu, 67Cu, 68Ga, 111In) that enable both therapeutic metal ion chelation and diagnostic imaging through PET or SPECT techniques, allowing a single compound to fulfill both treatment and monitoring roles.
Solution Approach 2:
The patent merges the therapeutic function of metal chelation with the diagnostic function of radiopharmaceutical imaging into a single unified compound system. By combining the metal-chelating 8-hydroxyquinoline core structure with radioisotope labels, the invention creates a theranostic agent that integrates both therapeutic and diagnostic capabilities in one molecule.
3Measurement precision
If 8-hydroxyquinoline derivatives are designed for high metal selectivity, then binding affinity for Cu and Zn ions is improved, but compound complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (hydroxyl at position 8, carbonyl groups, and heteroatoms) at strategic positions within the 8-hydroxyquinoline core structure. These localized functional features provide high metal binding selectivity for Cu and Zn ions, while the rest of the molecular framework remains relatively simple and tractable, balancing selectivity with structural manageability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These derivatives demonstrate superior binding affinity and metal selectivity, potentially offering both therapeutic benefits and diagnostic tools for neurological disorders like Alzheimer's disease, enhancing understanding and monitoring of disease progression.
Implementation Method 1
metal chelating agents may lead to the dissolution of Aβ deposits by preventing metal-Aβ interaction
Data Source
AI summary
The present application provides compounds useful in methods of treating neurological disorders such as Alzheimer's disease, and cancer such as prostate cancer. Also provided herein are radiolabeled compounds useful for imaging techniques, and techniques for diagnosis and monitoring of treatment of neurological disorders and cancer. An exemplary radiolabeled compound provided herein is useful as a radiotracer for positron emission tomography or single-photon emission computed tomography. Methods for preparing radiolabeled compounds and methods for preparing unlabeled compounds are also provided.